• Kodiak Sciences’ third-quarter 2026 net loss widened 8% year over year to $66.22 million.
• Research and development expenses rose 16% year over year to $58.3 million, driven by increased clinical and manufacturing activities.
• Quarter-end cash and cash equivalents totaled $88.68 million; subsequent common-stock sales under its at-the-market equity offering facility raised $69 million net.
• Zenkuda’s multi-indication biologics license application remains planned for fourth-quarter 2026, supported by five successful Phase 3 studies.
• Initial pivotal KSI-101 results are expected in December 2026, with a biologics license application planned for second-quarter 2027 if successful.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611121600PR_NEWS_USPR_____SF96888) on November 12, 2026, and is solely responsible for the information contained therein.